Please provide your email address to receive an email when new articles are posted on . “The cell-free DNA is the first blood-based test with performance that is comparable to current guideline ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
Patients with stages I-III screen-detected colorectal cancer (CRC) have better disease-free survival rates than those with non-screen–detected CRC, an effect that was independent of patient, tumor, ...
Validation of CanCatch Surf assay for tissue-agnostic detection of minimal residual disease in colorectal cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium ...